Mass spectrometry assay for congenital adrenal hyperplasia
US-10697980-B2 · Jun 30, 2020 · US
US10948501B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10948501-B2 |
| Application number | US-202016915729-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2020 |
| Priority date | Dec 24, 2008 |
| Publication date | Mar 16, 2021 |
| Grant date | Mar 16, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.
Opening claim text (preview).
That which is claimed is: 1. A method for determining the amount of 17-OH pregnenolone in a sample by mass spectrometry, the method comprising: (i) purifying the sample by liquid chromatography; (ii) ionizing the sample under conditions suitable to produce one or more 17-OH pregnenolone ions detectable by mass spectrometry, wherein the one or more 17-OH pregnenolone ions comprise one or more ions having a m/z of about 297.2±0.5, 105.6±0.5, and/or 91.1±0.5; (iii) determining the amount of the one or more 17-OH pregnenolone ions by mass spectrometry, wherein the method has a limit of quantitation of 6 ng/dL; and (iv) using the determined amount of the one or more ions to determine the amount of 17-OH pregnenolone in the sample. 2. The method of claim 1 , wherein said liquid chromatography is high performance liquid chromatography, ultra high performance liquid chromatography, or turbulent flow liquid chromatography. 3. The method of claim 1 , wherein the sample has been purified by solid phase extraction prior to ionization. 4. The method of claim 1 , further comprising adding internal standard to the sample, wherein an internal standard is used for determination of the amount of 17-OH pregnenolone in the sample. 5. The method of claim 4 , wherein the internal standard comprises an isotopically labeled analog of 17-OH pregnenolone. 6. The method of claim 1 , wherein the sample comprises plasma or serum. 7. The method of claim 1 , wherein the ionizing comprises ionization by electrospray ionization (ESI).
Chemical aspects of mass spectrometric analysis of biological material · CPC title
Electrospray ionisation · CPC title
Endocrine or metabolic disorders · CPC title
involving mass spectrometry · CPC title
related to pregnancy or the gonads · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.